<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00739388</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 30/07</org_study_id>
    <secondary_id>SWS-SAKK-30/07</secondary_id>
    <secondary_id>CDR0000612029</secondary_id>
    <nct_id>NCT00739388</nct_id>
  </id_info>
  <brief_title>Azacitidine in Treating Patients With Newly Diagnosed Previously Untreated or Secondary Acute Myeloid Leukemia Who Are Unsuitable For Intensive Chemotherapy</brief_title>
  <official_title>5-Azacytidine to Treat Acute Myeloid Leukemia in Elderly or Frail Patients Not Suitable for Intensive Chemotherapy. A Multicenter Phase II Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as azacitidine, work in different ways to stop&#xD;
      the growth of cancer cells, either by killing the cells or by stopping them from dividing.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well azacitidine works in treating patients with&#xD;
      acute myeloid leukemia who are unsuitable for treatment with intensive chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To evaluate the efficacy of azacitidine in patients with newly diagnosed or untreated&#xD;
           acute myeloid leukemia who are unsuitable for induction type chemotherapy because of age&#xD;
           or relevant comorbidities.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To evaluate survival and adverse events.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive azacitidine subcutaneously on days 1-5. Treatment repeats every 28 days for&#xD;
      6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months for 1 year and then&#xD;
      every 6 months for 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best response (complete or partial response)</measure>
    <time_frame>within 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>is defined as the time from trial registration until the date the criteria for either CR or PR are first met</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response duration</measure>
    <time_frame>is defined as the time from the date when the criteria for either CR or PR were first met until the date of relapse or death from any cause.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best response status</measure>
    <time_frame>within 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to hematological improvement (HI)</measure>
    <time_frame>is calculated for patients with HI and is defined as the time from trial registration until the date the criteria for HI are first met.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of HI</measure>
    <time_frame>is defined as the time from the date when the criteria for HI were first met until the date of relapse or death from any cause.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>is defined as the time from trial registration until progression, relapse or death from any cause, whichever occurs first.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>is defined as the time from trial registration until death from any cause.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events according to NCI CTCAE v3.0</measure>
    <time_frame>according to NCI CTCAE v3.0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted hospitalization time</measure>
    <time_frame>is defined as the time (nights) spent in hospital as a proportion of treatment duration (days).</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm: 5-azacytidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5-azacytidine 100 mg/m2/day s.c. on days 1-5 of a 28-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azacytidine</intervention_name>
    <description>100 mg/m2/day s.c. on days 1-5 of a 28-day cycle</description>
    <arm_group_label>Arm: 5-azacytidine</arm_group_label>
    <other_name>Azacitidine</other_name>
    <other_name>5-azacytidine</other_name>
    <other_name>Vidaza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of 1 of the following:&#xD;
&#xD;
               -  De novo acute myeloid leukemia (AML)&#xD;
&#xD;
               -  AML secondary to prior hematological disease or cytotoxic treatment&#xD;
&#xD;
          -  Newly diagnosed or untreated disease&#xD;
&#xD;
          -  At least 20% blasts in the blood or bone marrow or extramedullary disease&#xD;
&#xD;
          -  Must be considered unsuitable for intensive chemotherapy due to ≥ 1 of the following:&#xD;
&#xD;
               -  High age or frail for the biologic age&#xD;
&#xD;
               -  Relevant comorbidities&#xD;
&#xD;
               -  Unwilling to undergo intensive chemotherapy&#xD;
&#xD;
          -  No chronic myelogenous leukemia or acute promyelocytic leukemia&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  WHO performance status 0-3&#xD;
&#xD;
          -  Bilirubin ≤ 3 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 times ULN&#xD;
&#xD;
          -  AST ≤ 2.5 times ULN&#xD;
&#xD;
          -  Serum creatinine ≤ 2.5 times ULN&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 12 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  Patient compliance and geographic proximity allow proper staging and follow-up&#xD;
&#xD;
          -  No NYHA class III-IV heart failure or relevant cardiac arrhythmia&#xD;
&#xD;
          -  No active hematological/oncological disease other than AML&#xD;
&#xD;
          -  No psychiatric disorder precluding understanding of information on trial related&#xD;
             topics or giving informed consent&#xD;
&#xD;
          -  No serious underlying medical condition in the judgment of the investigator, which&#xD;
             could impair the ability of the patient to participate in the trial, including but not&#xD;
             limited to, any of the following:&#xD;
&#xD;
               -  Active autoimmune disease&#xD;
&#xD;
               -  Uncontrolled diabetes&#xD;
&#xD;
               -  Active uncontrolled infection&#xD;
&#xD;
               -  HIV infection&#xD;
&#xD;
               -  Active chronic hepatitis B or C infection&#xD;
&#xD;
          -  No known allergy or hypersensitivity to azacitidine or mannitol&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior treatment for AML&#xD;
&#xD;
          -  No prior azacitidine or decitabine&#xD;
&#xD;
          -  No other concurrent experimental or investigational drugs or anticancer therapy&#xD;
&#xD;
          -  More than 30 days since participation in another clinical trial&#xD;
&#xD;
          -  No concurrent growth factors for use in afebrile and asymptomatic patients except to&#xD;
             treat neutropenic infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jakob Passweg, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Hopitaux Universitaires de Geneve</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sabine Blum, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Hospitalier Universitaire Vaudois</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kantonspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>CH-5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Baden</name>
      <address>
        <city>Baden</city>
        <zip>CH-5404</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital-Basel</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Institute of Southern Switzerland</name>
      <address>
        <city>Bellinzona</city>
        <zip>CH-6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalzentrum Biel</name>
      <address>
        <city>Biel</city>
        <zip>CH-2500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital, Luzerne</name>
      <address>
        <city>Luzerne</city>
        <zip>CH-6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital - St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires de Geneve</name>
      <address>
        <city>Thonex-Geneve</city>
        <zip>CH-1226</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitaetsSpital Zuerich</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Passweg JR, Pabst T, Blum S, Bargetzi M, Li Q, Heim D, Stussi G, Gregor M, Leoncini L, Meyer-Monard S, Brauchli P, Chalandon Y; Swiss Group for Clinical Cancer Research (SAKK). Azacytidine for acute myeloid leukemia in elderly or frail patients: a phase II trial (SAKK 30/07). Leuk Lymphoma. 2014 Jan;55(1):87-91. doi: 10.3109/10428194.2013.790540. Epub 2013 May 2.</citation>
    <PMID>23547838</PMID>
  </results_reference>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>August 20, 2008</study_first_submitted>
  <study_first_submitted_qc>August 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2008</study_first_posted>
  <last_update_submitted>April 9, 2013</last_update_submitted>
  <last_update_submitted_qc>April 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>adult acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>adult acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>adult acute myelomonocytic leukemia (M4)</keyword>
  <keyword>adult acute monoblastic leukemia (M5a)</keyword>
  <keyword>adult acute monocytic leukemia (M5b)</keyword>
  <keyword>adult erythroleukemia (M6a)</keyword>
  <keyword>adult pure erythroid leukemia (M6b)</keyword>
  <keyword>adult acute megakaryoblastic leukemia (M7)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

